絞り込み

16603

広告

キンギョの「設計図」解読 (デイリースポーツ)

キンギョのゲノム(全遺伝情報)解読に初めて成功したと、大阪大などのチームが26日付の米科学誌電子版に発表した。ゲノムは生物の設計図ともいわれ、さまざまな形態を持...

  1. 家畜ふん尿:お得に燃料 阪大開発 秋に北...
  2. 科学の森:続く黒潮大蛇行、影響は 12年...
  3. 今どきサイエンス:文化としての科学=鴨志...
  4. 深海アイドル図鑑:/97 宝石サンゴ (...

ニュース一覧

Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab: A Prospective, Randomized, Open-Label Trial.

著者 Niimi R , Kono T , Nishihara A , Hasegawa M , Kono T , Sudo A
JBMR Plus.2018 Sep ; 2(5):289-294.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (75view , 0users)

Full Text Sources

Miscellaneous

There is no consensus on an optimal treatment after daily teriparatide (TPTD). We performed a prospective, randomized, open-label, 12-month trial to investigate the efficacy of follow-up treatment after daily TPTD treatment for Japanese patients. Three-hundred patients were enrolled in this study. Patients received oral bisphosphonate (BP) including alendronate (ALN; 35 mg/week) and minodoronate (MINO; 50 mg/month), or subcutaneous denosumab (60 mg/6 month). The primary efficacy measure was bone mineral density (BMD) responses in the lumbar spine (LS) and femoral neck (FN). Lumbar spine BMD increased by 1.3 ± 5.1% in the ALN subgroups, 0.5 ± 4.6% in the MINO subgroups, and 4.3 ± 3.5% in the denosumab subgroups. Femoral neck BMD increased by 0.7 ± 4.6% in the ALN subgroups, 0.2 ± 4.6% in the MINO subgroups, and 1.4 ± 3.4% in the denosumab subgroups. Lumbar spine BMD increases were significantly greater in the denosumab subgroup than the BP subgroups. There were no significant differences in FN BMD increases among the three subgroups. Lumbar spine BMD increases were significantly greater in the denosumab subgroup than the BP subgroups, whereas FN BMD increases were not significant. Denosumab treatment was more effective in increasing BMD and therefore has the potential benefit of fracture prevention. Further research is warranted to determine the optimal treatment after daily TPTD. © 2018 The Authors. published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
PMID: 30283910 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード